MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.28 USD
-0.11 (-3.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.29 +0.01 (0.30%) 6:30 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 321 - 340 ( 364 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
DART''s A Potential Alternative To CAR-T''s
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Blinatumomab''s Approval Sets the Stage for Potentially Superior DARTs
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MGD007, Unleashing the Power of TCells on Colon Cancer
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Compelling Pipeline Opportunities at the Cutting Edge of Immuno-Oncology
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Deliberate Change of Course, But Details Still Sketchy
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Q3 EPS, Focuses on Breast Cancer Opportunity with Margetuximab, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Takeda Expands Deal with Potential $1.6B in Additional Commitments
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Takeda Expands DART Collaboration, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Takeda Expands DART Collaboration, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Pipeline Advances, But Limited Near- Term Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.